WAUKEGAN, Ill.--(BUSINESS WIRE)--NeoPharm, Inc. (NASDAQ: NEOL - News) today announced that it has enrolled its first patients in its multi-center open-label, Phase II clinical trial of Liposomal Paclitaxel (LEP-ETU) for efficacy and safety in patients with Metastatic Breast Cancer. In pre-clinical and Phase I clinical data, LEP-ETU demonstrated a reduced side-effect profile, particularly peripheral neuropathy, as well as the potential for increased dosage and greater efficacy over Taxol®, the standard care for many tumors, principally breast and ovarian cancer.
